Expression of Genes for Platelet Aggregation Up Post-CABG

This article originally appeared here.
Share this content:
Expression of Genes for Platelet Aggregation Up Post-CABG
Expression of Genes for Platelet Aggregation Up Post-CABG

(HealthDay News) – Following coronary artery bypass graft (CABG) surgery, there is increased expression of genes involved in platelet aggregation, including cyclooxygenase-1 (COX1), glycoprotein (GP)IIb and GPIIIa, according to a study published online Feb. 13 in the Journal of Thrombosis and Haemostasis.

To investigate whether post-CABG surgery platelets are associated with a prothrombotic state, Sarah-Jayne Reilly, PhD, of the Karolinska Institutet in Stockholm, and colleagues sampled blood and purified platelets from 11 patients before and three to six days after CABG. For seven of the patients, gene expression profiling was performed using low density array plates.

The researchers found that, of the 45 genes examined, those that were significantly up-regulated were GPIIb, GPIIIa, and COX-1. In four additional patients, the results were confirmed, including flow cytometry of the GPIIb/IIIa receptor.

"CABG surgery up-regulates mRNA and protein levels of proteins that are key players in platelet aggregation," the authors write. "Marked elevation of GPIIb/IIIa mRNA levels results in significantly increased GPIIb/IIIa expression in platelets post-CABG surgery, which may be a reason for increased thrombus formation and myocardial infarction after CABG."

Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs